Cost-effectiveness of financial incentives to improve glycemic control in adults with diabetes: A pilot randomized controlled trial.
Leonard E EgedeRebekah J WalkerClara E Dismuke-GreerSarah PyzykAprill Z DawsonJoni S WilliamsJennifer A CampbellPublished in: PloS one (2021)
Given ICERs of prior diabetes interventions range from $1,000-$4,000, a cost of $1,100 per 1% within group decrease in HbA1c is a promising intervention. Multi-component incentive structures seem to have the least variation in cost-effectiveness.
Keyphrases
- glycemic control
- type diabetes
- blood glucose
- weight loss
- insulin resistance
- randomized controlled trial
- study protocol
- high resolution
- cardiovascular disease
- open label
- metabolic syndrome
- smoking cessation
- clinical trial
- double blind
- adipose tissue
- young adults
- hepatitis c virus
- human immunodeficiency virus
- hiv infected
- affordable care act